EGFR and neoplasm: Despite all of the above knowledge, however, objective response to anti-EGFR antibody therapy in metastatic colorectal cancer is obtained, at best, in no more than half of patients without tumor aberrations in the EGFR signaling network that are currently tested in routine practice [9], [19], [20].